FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & Compounded "semaglutide" is not FDA approved semaglutide.com